Evidence-Based Guide

Recurrent Yeast Infection

A physician's evidence-based guide to recurrent vulvovaginal candidiasis: why infections keep coming back, fluconazole suppression, and the newer treatments oteseconazole and ibrexafungerp.

Medically reviewed by Parth Bhavsar, MD
Last reviewed: September 8, 2026
20 min read

What is the best treatment for recurrent yeast infections in 2026?

Recurrent vulvovaginal candidiasis, defined as four or more episodes a year, affects roughly 5 to 9 percent of women and an estimated 138 million people worldwide each year.[2][3] The evidence-based cornerstone is induction treatment to clear the current episode followed by maintenance suppression, classically oral fluconazole 150 mg once weekly for six months. In the landmark Sobel trial, 90.8 percent of women on weekly fluconazole stayed disease-free at six months versus 35.9 percent on placebo.[1] Since 2021 the FDA has approved two newer oral options purpose-built for recurrent disease: oteseconazole (Vivjoa), which cut recurrence to roughly 5 percent through 48 weeks, and monthly ibrexafungerp.[5][6] Because recurrence can unmask diabetes, a resistant or non-albicans strain, or another diagnosis, the underlying cause should be identified rather than only suppressing symptoms.
Medically reviewed by Parth Bhavsar, MD. Updated September 8, 2026.

Key Takeaways

  • Recurrent infection means four or more culture-confirmed episodes in a year, affecting 5 to 9 percent of women.[2]
  • Recurrence usually reflects a host predisposition and relapse of the woman's own strain, not a single infection that was never cured.[14]
  • Weekly fluconazole 150 mg for six months is the classic suppression and kept 90.8 percent of women disease-free versus 35.9 percent on placebo.[1]
  • Oteseconazole (Vivjoa) reduced recurrence to roughly 5 percent through 48 weeks versus about 40 percent for placebo.[5]
  • Monthly ibrexafungerp is a newer non-azole preventive option.[6]
  • When suppression fails, test for non-albicans species such as C. glabrata and azole resistance, and consider boric acid or specialist referral.[9]
Editorial medical illustration representing recurrent yeast infection
Recurrent vulvovaginal candidiasis: why it comes back and how it is treated, from the TeleDirectMD medical team.

A yeast infection that clears and then comes back is one of the more frustrating problems in primary care, both for the people who have it and for the clinicians trying to stop it. The good news is that the evidence base has grown considerably, and there are now more options than ever, including two medicines approved specifically for this situation.

What Counts as Recurrent

Recurrent vulvovaginal candidiasis (RVVC) is usually defined as four or more episodes of symptomatic, confirmed yeast infection in a 12-month period. A finer distinction matters: true recurrent infection is not one stubborn infection that was never fully cleared; it is repeated new episodes from a person's own reservoir of Candida, usually the same strain returning again and again.[14]

Roughly 75 percent of women will have at least one episode in their lifetime, but only 5 to 9 percent cross into the recurrent range. A large systematic review estimated recurrent vulvovaginal candidiasis affects about 138 million women worldwide each year, making it one of the most common chronic vaginal conditions on the planet.[2][3]

Recurrent vs Uncomplicated Infection

FeatureUncomplicated VVCRecurrent (RVVC)
DefinitionInfrequent, mild to moderate4 or more episodes per year[2]
PrevalenceUp to 75 percent lifetime5 to 9 percent of women[3]
ApproachShort azole courseInduction then long-term suppression[1]
Culture before treatingOften unnecessaryRecommended to confirm species[11]

Why Infections Recur

Recurrence is usually a property of the host rather than the bug. The same Candida albicans that lives harmlessly in most women relapses in a minority because of how their body responds. Well-documented contributors include:[10]

  • Repeated antibiotic exposure, which repeatedly strips protective lactobacilli
  • Diabetes, especially with poor glucose control, a classic driver of recurrent infection
  • Hormonal factors, including high-estrogen contraceptives and the premenstrual estrogen rise
  • Immune factors, from immunosuppression or, in many otherwise healthy women, a subtle but poorly understood local susceptibility
  • Resistance or species shift, including fluconazole resistance and non-albicans species such as C. glabrata

The Relapse Mechanism

In most recurrent cases the organism is C. albicans that remains fully sensitive to fluconazole, which tells you the problem is not the drug failing but the host's tendency to let the fungus re-establish itself. After a course of treatment, the vagina repopulates, and in susceptible women the yeast out-competes the recovering lactobacilli again. This is why suppression, not repeated one-off treatment, is the effective strategy, and why the moment suppression stops, the relapse risk returns.[14][1]

A long-term follow-up study reinforced this: even after completing a successful suppressive course, a substantial proportion of women relapse, and long-term cure of the tendency remains difficult.[4]

Diagnosing Recurrent VVC

Before committing someone to months of suppression, the diagnosis should be confirmed on culture, and the species identified. This is not pedantry: several conditions mimic recurrent yeast, including recurrent bacterial vaginosis, allergic or irritant dermatitis, and lichen sclerosus, and they need entirely different management. Culture also reveals whether a non-albicans species is driving the relapses, which changes the treatment choice.[11][9]

Induction Then Suppression

The standard structure of treatment has two phases:[1]

  • Induction: clear the current episode, classically with fluconazole 150 mg every 72 hours for three doses.
  • Maintenance: ongoing suppression to prevent the next episode, classically weekly fluconazole 150 mg for six months.
The induction-then-maintenance protocolStandard structure for managing recurrent infectionInduction3 dosesMaintenance6 monthsObservationoff therapyMost relapses occur after maintenance stops.Source: Sobel 2004; IDSA 2016
The standard induction-then-maintenance protocol for recurrent vulvovaginal candidiasis.[1][11]

Weekly Fluconazole: The Evidence

The landmark randomized trial by Sobel and colleagues (2004) randomly assigned 387 women with recurrent infection to six months of weekly fluconazole 150 mg or placebo, after induction. Women on fluconazole stayed disease-free at 6, 9, and 12 months at rates of 90.8 percent, 73.2 percent, and 42.9 percent, versus 35.9 percent, 27.8 percent, and 21.9 percent on placebo. Median time to the next episode was 10.2 months versus 4.0 months. No fluconazole resistance emerged, and the drug was discontinued in only one patient (for headache).[1]

Suppression controls recurrenceDisease-free survival during and after weekly fluconazole020406080100104150228247268283Weekly fluconazole (disease-free %)Placebo (disease-free %)6 mo9 mo12 moSource: Sobel 2004 (NEJM)
Disease-free survival declines after fluconazole maintenance stops, underscoring that suppression controls rather than cures the tendency.[1]

The key nuance is visible in those numbers: the benefit is strong while on the drug and decays once it is stopped. Suppression controls the tendency; it does not cure it. For many women, repeating or extending suppression, or moving to a newer agent, is part of a long-term management conversation.[1]

Oteseconazole (Vivjoa)

Oteseconazole is a selective, long-acting oral azole approved in 2022 specifically for recurrent vulvovaginal candidiasis. In the paired VIOLET phase 3 trials, women with recurrent infection were given a short induction (two 150 mg doses a day, then weekly doses) after their acute episode cleared with fluconazole. Through 48 weeks, only 6.7 percent and 3.9 percent of oteseconazole-treated women had a recurrence in the two trials, versus 42.8 percent and 39.4 percent for placebo, a dramatic difference. Side effects were generally mild, with no drug-related serious events and no concerning liver or QT findings.[5]

Ibrexafungerp (Brexafemme)

Ibrexafungerp is the first oral non-azole antifungal, a triterpenoid that blocks glucan synthase, a target azoles do not touch. Because it is not an azole, it can treat some fluconazole-resistant strains, and cross-resistance is limited. For acute infection it is taken as two 150 mg doses 12 hours apart. For prevention, the 2025 CANDLE trial of monthly ibrexafungerp found 70.8 percent of treated women had no recurrence versus 58.5 percent on placebo, with the benefit sustained for months after the last dose.[6][7]

Recurrence at the primary endpointProportion with recurrence across preventive strategies (note differing windows)Placebo (6 months)64.1%Monthly ibrexafungerp (to test-of-cure)29.2%Weekly fluconazole (6 months)9.2%Oteseconazole (48 weeks)5.3%Source: Sobel 2004; Sobel NEJM Evid 2022; Goje 2025
Recurrence rates at the primary endpoint across preventive strategies (note the differing observation periods).[1][5][6]

Boric Acid

Boric acid vaginal capsules (typically 600 mg inserted nightly for 14 days) are a long-standing tool for infection that resists azoles or relapses despite them, particularly for non-albicans species. A clinical review concluded boric acid achieves mycologic cure in a substantial share of women with azole-resistant or non-albicans infection, though it is reserved for these situations rather than used first-line.[8]

Non-albicans and Resistant Yeast

When a properly diagnosed infection fails standard treatment, think species and resistance. Candida glabrata, the most common non-albicans species, is frequently less susceptible to fluconazole, and acquired azole resistance in C. albicans is increasingly reported. Management shifts to culture-guided therapy, longer topical courses, boric acid, or the newer non-azole agents, sometimes with specialist input.[9]

Preventive Strategies Compared

StrategyDosingKey result vs placebo
Weekly fluconazole (6 months)150 mg once weekly90.8% disease-free at 6 months vs 35.9%[1]
Oteseconazole (Vivjoa)Short induction then weeklyAbout 5% recurrence through 48 weeks vs about 40%[5]
Monthly ibrexafungerp300 mg monthly70.8% recurrence-free vs 58.5%[6]
Boric acid capsules600 mg nightly for 14 daysFor azole-resistant or non-albicans infection[8]

Lifestyle and Adjuncts

Beyond medication, a few changes can reduce the drivers of recurrence: control diabetes tightly, avoid unnecessary antibiotics, skip douching and scented products, and address modifiable hormonal exposures with your clinician.[10] The evidence for probiotics is limited and low-certainty; a Cochrane review found they may provide a modest benefit when added to antifungal therapy but cannot replace it.[13]

Looking for an Underlying Cause

DriverCheckIntervention
DiabetesFasting glucose, HbA1cTight glycemic control[10]
Non-albicans or resistant yeastCulture with susceptibilityBoric acid, longer topical, or non-azole agent[9]
Antibiotic exposureMedication historyAvoid unnecessary antibiotics[10]

Red Flags

Seek care promptly if recurrent infection is accompanied by diabetes symptoms (excessive thirst or urination), if symptoms worsen despite treatment, or if discharge becomes malodorous, bloody, or associated with pelvic pain. These may indicate an uncontrolled underlying condition, a resistant organism, or a different diagnosis such as pelvic inflammatory disease.[10][9]

For the full diagnosis and first-line treatment framework, see the yeast infection guide, and for the antifungal used in suppression, the fluconazole guide.

Frequently Asked Questions

Four or more episodes of symptomatic, confirmed yeast infection in a 12-month period. It affects roughly 5 to 9 percent of women.[2][3]

Recurrence usually reflects a personal predisposition, with common drivers including repeated antibiotic use, diabetes, hormonal factors, and sometimes a resistant or non-albicans Candida strain. It is typically relapse of your own yeast rather than a single infection that was never cured.[14]

The proven approach is induction to clear the current episode followed by long-term suppression, classically weekly fluconazole for six months, with newer options such as oteseconazole and monthly ibrexafungerp for those who relapse.[1]

Weekly fluconazole kept about 91 percent of women disease-free at six months, dropping to about 43 percent at 12 months (six months after stopping). The benefit lasts while taking the drug and decays afterward, so suppression is often repeated or extended.[1]

Oteseconazole is a newer, long-acting option designed specifically for recurrent infection. In its trials it cut recurrence to roughly 5 percent through 48 weeks versus about 40 percent for placebo, a strong result, and it offers an alternative for women who relapse on weekly fluconazole.[5]

Boric acid vaginal capsules (600 mg nightly for 14 days) can clear azole-resistant and non-albicans infections that keep relapsing, but it is reserved for those situations rather than used as first-line treatment.[8]

Candida glabrata is the most common non-albicans species causing vaginal infection, and it is frequently less susceptible to fluconazole. When your current infection is glabrata, treatment often shifts to boric acid, longer topical courses, or a non-azole agent.[9]

Yes, recurrent yeast infection is a recognized clue to undiagnosed or poorly controlled diabetes. Controlling blood glucose is one of the most effective interventions for reducing recurrence.[10]

No. Yeast infection is not sexually transmitted, and treating a partner does not reduce a woman's recurrence rate. The reservoir for recurrence is the individual's own Candida, not reinfection from a partner.[12]

Consider referral when infection recurs despite appropriate suppression, when culture shows a resistant or non-albicans species, or when the diagnosis is uncertain and symptoms are not responding as expected.[9][11]

References

  1. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876-883. doi:10.1056/NEJMoa033114
  2. Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(10):e339-e347. doi:10.1016/S1473-3099(18)30103-8
  3. Foxman B, Muraglia R, Dietz JP, Sobel JD. Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from the first global systematic survey. J Low Genit Tract Dis. 2013;17(1):45-52. doi:10.1097/LGT.0b013e318273e8cf
  4. Crouss T, Sobel JD, Smith K, Nyirjesy P. Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Antifungal Therapy. J Low Genit Tract Dis. 2018;22(4):298-302. doi:10.1097/LGT.0000000000000413
  5. Sobel JD, Donders G, Degenhardt T, et al. Efficacy and Safety of Oteseconazole in Recurrent Vulvovaginal Candidiasis. NEJM Evid. 2022;1(8):EVIDoa2100055. doi:10.1056/EVIDoa2100055
  6. Goje O, Azie NE, Angulo DA, et al. A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (CANDLE). Am J Obstet Gynecol. 2025. doi:10.1016/j.ajog.2025.07.040
  7. Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303). Clin Infect Dis. 2022;74(11):1979-1985. doi:10.1093/cid/ciab750
  8. Iavazzo C, Gkegkes ID, Zarkada IM, Falagas ME. Boric acid for recurrent vulvovaginal candidiasis: the clinical evidence. J Womens Health (Larchmt). 2011;20(8):1245-1255. doi:10.1089/jwh.2010.2708
  9. Akinosoglou K, Livieratos A, Asimos K, et al. Fluconazole-Resistant Vulvovaginal Candidosis: An Update on Current Management. Pharmaceutics. 2024;16(12):1555. doi:10.3390/pharmaceutics16121555
  10. Patel DA, Gillespie B, Sobel JD, et al. Risk factors for recurrent vulvovaginal candidiasis in women receiving maintenance antifungal therapy. Am J Obstet Gynecol. 2004;190(3):644-653. doi:10.1016/j.ajog.2003.11.027
  11. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ933
  12. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1
  13. Xie HY, Feng D, Wei DM, et al. Probiotics for vulvovaginal candidiasis in non-pregnant women. Cochrane Database Syst Rev. 2017;11(11):CD010496. doi:10.1002/14651858.CD010496.pub2
  14. Rautemaa-Richardson R, Sobel JD, Stone N, et al. State-of-the-Art Review: Managing Vulvovaginal Candidiasis. Clin Infect Dis. 2026. doi:10.1093/cid/ciaf673

About the Author

Parth Bhavsar, MD

Dr. Bhavsar is a board-certified family medicine physician and founder of TeleDirectMD. He manages recurrent vulvovaginal candidiasis by confirming the diagnosis, screening for underlying causes such as diabetes, and matching the suppression strategy to each patient. He practices telemedicine across 44 U.S. states and DC.

Medically reviewed by Parth Bhavsar, MD. Last reviewed September 8, 2026.